Tourette's Syndrome is a neuropsychiatric disorder that is marked by a collection of motor- and vocal tics. Tourette's is inherited and is believed to result from dysfunctional cortical and subcortical regions in the brain. Since the mechanism behind the development of Tourette's is unknown it is difficult to predict the therapeutic potential of cannabinoids. However, many patients report significant symptomatic relief after (self-)administration of cannabis, suggesting cannabinoids can be used to (help) treat Tourette's.
Self-medicating patients (n=47) reported symptomatic relief from Tourette’s after consumption of nicotine (7%), alcohol (69%) or cannabis (85%), indicating therapeutic potential for cannabinoids in Tourette’s (Müller-Vahl et al., 1997). In a 17-patient trial, 6 weeks of treatment with up to 10 mg THC/day produced significant symptomatic relief (Müller-Vahl et al., 2003).
Several single-patient case reports mention significant to complete symptomatic relief after using cannabis (see references within: Kluger et al., 2015).
Kluger, B., Triolo, P., Jones, W., and Jankovic, J. (2015). The therapeutic potential of cannabinoids for movement disorders. Mov. Disord. Off. J. Mov. Disord. Soc.
Müller-Vahl, K.R., Kolbe, H., and Dengler, R. (1997). [Gilles de la Tourette syndrome. Effect of nicotine, alcohol and marihuana on clinical symptoms]. Nervenarzt 68, 985–989.
Müller-Vahl, K.R., Schneider, U., Prevedel, H., Theloe, K., Kolbe, H., Daldrup, T., and Emrich, H.M. (2003). Delta 9-tetrahydrocannabinol (THC) is effective in the treatment of tics in Tourette syndrome: a 6-week randomized trial. J. Clin. Psychiatry 64, 459–465.